. 2022 Jun 9;95(1):e27900. doi: 10.1002/jmv.27900

Table 3.

Bivariate meta‐analysis of different HPV16 and HPV18 serological markers: pooled sensitivity and specificity by assay type

	Marker name	Study reference number	Number of studies	Endpoint	Sensitivity (95% CI)	Specificity (95% CI)	DOR (95% CI)
HPV serology (ELISA)	HPV16 and HPV18 (E6 and E7)	d2a, d2b, d2c, d2d	4	CIN2+	18.0 (15–21)	96.0 (92.0–98.0)	5.00 (2.00–11.00)
HPV serology (multiplex HPV serology immunofluorescent assay)	HPV16 and HPV18 E6, E7, and E4	d3a, d3b, d3c, d3d, d3e	5	ICC	16.0 (8.45–28.6)	98.0 (97.0–99.0)	9.72 (3.95–23.93)
HPV serology (immunoenzymatic assay (slot‐blot))	HPV16 E7 and E4	d1a, d1b	2	CIN2+	28.9 (23.3–35.1)	72.0 (66.6–77.0)	1.05 (0.72–1.52)

Marker name

Study reference number

Number of studies

Endpoint

Sensitivity (95% CI)

Specificity (95% CI)

DOR (95% CI)

HPV serology (ELISA)

HPV16 and HPV18 (E6 and E7)

d2a, d2b, d2c, d2d

CIN2+

18.0 (15–21)

96.0 (92.0–98.0)

5.00 (2.00–11.00)

HPV serology

(multiplex HPV serology immunofluorescent assay)

HPV16 and HPV18 E6, E7, and E4

d3a, d3b, d3c, d3d, d3e

ICC

16.0 (8.45–28.6)

98.0 (97.0–99.0)

9.72 (3.95–23.93)

HPV serology

(immunoenzymatic assay (slot‐blot))

HPV16 E7 and E4

d1a, d1b

CIN2+

28.9 (23.3–35.1)

72.0 (66.6–77.0)

1.05 (0.72–1.52)

Abbreviations: CI, confidence interval; DOR, diagnostic odds ratio; ELISA, enzyme‐linked immunosorbent assay; HPV, human papillomavirus; ICC, invasive cervical cancer.